Clinical trials: Rejection
Kidney Transplantation
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin…
- Trial name
- NCT00235781
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Kidney Transplant Rejection, Kidney Transplant Failure
Protocol Biopsies in High-risk Renal Transplant Recipients
The present study aims to evaluate the usefulness of protocol biopsies in a cohort of renal transplant patients of high immunological risk for graft injury and loss.
- Conditions
- Kidney Transplant Rejection, Kidney Transplant Failure, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- NCT04154267
- Testing
- Percutaneous renal biopsy.
- Where
- Brazil
- Volunteers
- 119 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Kidney Disease
Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy
This study is intended to help doctors learn about the relationships between specific genetic makeup (gene markers) and the development of chronic rejection.
- Trial name
- NCT00006328
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Kidney Transplantation, Kidney Allograft Biopsy
Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation
We will study a prospective cohort including all kidney transplant recipients undergoing kidney graft biopsy in one kidney transplantation center, for a duration of 5 years.
- Conditions
- Kidney Transplantation, Kidney Allograft Biopsy, Humoral Rejection, Microvascular Inflammation
- Trial name
- RECITE (NCT05890430)
- Testing
- Blood draw, Urine draw
- Volunteers
- 570 people
- Sponsor
- University Hospital, Strasbourg, France
Heart Transplant Failure and Rejection
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
Immunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and elimination of these agents.
- Trial name
- NCT04380311
- Testing
- Tacrolimus Dosing Support Tool
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Despite advances in lung transplantation, the median survival remains only 55% at 5 years. The main limitation to long term survival is the development of chronic lung allograft dysfunction.
- Trial name
- PIRCLAD (NCT03359863)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Antibody Mediated Rejection of Kidney Transplant
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an…
- Trial name
- NCT02936479
- Testing
- C1-INH (Berinert)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
CMV Disease, Viral Resistance
Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients
CMV viral disease negatively affects transplant patients. CMV is the most prevalent infection in transplant patients and 3 month drug regimens to prevent the virus have been mostly unsuccessful, usually after the drug has been…
- Conditions
- CMV Disease, Viral Resistance, Rejection, Death
- Trial name
- NCT00225394
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Massachusetts, Worcester
Heart Transplant Rejection
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart…
- Trial name
- ProTECT (NCT05205551)
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Natera, Inc.
Heart Transplant Failure and Rejection
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first…
- Trial name
- DETECT (NCT05081739)
- Testing
- Prospera Transplant Assessment, Endomyocardial biopsy
- Sponsor
- Natera, Inc.
Lung Transplant Rejection
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous immunoglobulins for AMR after lung transplantation…
- Trial name
- NCT02474927
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- John F. McDyer, MD
Rejection Chronic Renal, Kidney Transplant Rejection
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection (ABMR).
- Trial name
- NCT03859388
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplant
Tissue Study on the Chronic Active Humoral Rejection (cAMR) Population of Kidney Transplantation
The study is tissue-based, retrospective and prospective, single-centre, non-sponsored. Primary objective: To examine patient and organ survival and eGFR variation in kidney transplant patients diagnosed histologically with cAMR.
- Trial name
- NCT06794970
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
End Stage Renal Disease
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus.
- Trial name
- NCT03321656
- Testing
- Tacrolimus, Envarsus XR
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Roberto Gedaly
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or…
- Trial name
- NCT03605654
- Testing
- MDR-102, Immunosuppressive Agents
- Sponsor
- Medeor Therapeutics, Inc.
Antibody-mediated Rejection, Allosensitization
Isatuximab in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor…
- Trial name
- NCT05862766
- Testing
- Isatuximab, bone marrow biopsy
- Where
- United States
- Sponsor
- NYU Langone Health
Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on triple maintenance immunosuppression, which means that patients take 3 types of immunosuppression drugs to suppress their immune system…
- Trial name
- NCT02974686
- Testing
- Everolimus, Mycophenolic Acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Chronic Antibody-mediated Transplant Rejection
Bortezomib in Rejection of Kidney Transplants
The purpose of the study is to assess the efficacy of bortezomib, in association with steroids, plasma exchange, and polyclonal intravenous immunoglobulins, in the treatment of chronic antibody mediated rejection due to donor…
- Trial name
- TRIBUTE (NCT02201576)
- Testing
- Bortezomib, Plasma exchanges and intravenous immunoglobulins
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris